NCT06241482 Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care
| NCT ID | NCT06241482 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai 6th People's Hospital |
| Condition | Neurocritical Care |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-10-15 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-10-15 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Enhanced recovery after surgery (ERAS) is a strategy of perioperative management aimed to accelerate the rehabilitation of patients through various optimized perioperative managements as well as ongoing adherence to a patient-focused, multidisciplinary, and multimodal approach. Alleviating the injury and stress caused by surgery or disease is the core principle of ERAS, which has been shown to reduce complication rates after surgery, promote patient recovery, decrease hospital length of stay and reduce costs. ERAS has been widely applied in many surgical perioperative fields, and it has achieved remarkable effects. However, there are few applications of ERAS in neurosurgery, especially in clinical trials of neurocritical care patients. Therefore, the investigators attempt to conduct the study of ERAS in neurosurgical intensive patients using a series of optimized perioperative managements that have been verified to be effective by evidence-based medicine, and to evaluate the safety and effectiveness of ERAS in neurocritical care. The aim of this study is to explore the most suitable ERAS protocols to accelerate the postoperative rehabilitation process of neurocritical care patients, and to provide more evidence-based medicine for the effectiveness and safety of ERAS in neurosurgery.
Eligibility Criteria
Inclusion Criteria: * Age 18-75 years old * Patients with moderate or severe acute traumatic brain injury or cerebrovascular disease requiring neurosurgical intensive care treatment * Hospitalization time ≥ 1 week * The guardian is able to understand and actively cooperate in completing the project * The guardian signs an informed consent form Exclusion Criteria: * Patients undergoing non-surgical treatment * Patients diagnosed as brain death within the first 24 hours after admission to NICU * Patients undergoing cardiopulmonary resuscitation, maintenance dialysis, end-stage tumors, and disseminated cancer * Patients who withdraw treatment during hospitalization or are discharged automatically * Patients who underwent unplanned secondary surgery during the research process * Individuals who cannot be followed up during the research process
Contact & Investigator
Hao Chen, M.D., Ph.D.
STUDY DIRECTOR
Shanghai 6th Peoples' Hospital
Frequently Asked Questions
Who can join the NCT06241482 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Neurocritical Care. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06241482 currently recruiting?
Yes, NCT06241482 is actively recruiting participants. Contact the research team at hao.chen@shsmu.edu.cn for enrollment information.
Where is the NCT06241482 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06241482 clinical trial?
NCT06241482 is sponsored by Shanghai 6th People's Hospital. The principal investigator is Hao Chen, M.D., Ph.D. at Shanghai 6th Peoples' Hospital. The trial plans to enroll 80 participants.